Drugs / P63+ lung progenitors
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06946953 | Mar 2025 → Dec 2029 expected | chronic obstructive pulmonary disease | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P63+ lung progenitors | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06946953 ↗ |
| Action | Restore | “repair damaged lung tissue and improve lung function” NCT06946953 ↗ |
| Modality | Cell therapy | “autologous bronchial basal cell therapy” NCT06946953 ↗ |
| Route | Other | “administered via fiberoptic bronchoscopy to each lung segment” NCT06946953 ↗ |